Health Canada Approves Use of Radioiosotope Agent to Diagnose IBD, Detect GI Infection

Health Canada Approves Use of Radioiosotope Agent to Diagnose IBD, Detect GI Infection
Health Canada has approved use of the nuclear medicine imaging kit Drax Exametazime to help in the diagnosis of inflammatory bowel disease (IBD), Produced by Jubilant Radiopharma and already approved in the United States, Drax Exametazime is used in nuclear medicine to assist in the location of infections when its source cannot be identified. Such identification is critical to accurate diagnoses and disease characterization, and is a fundamental first step in developing treatment plans. “We are very pleased that Drax Exametazime is now available to patients in Canada,” Pramod Yadav, CEO of Jubilant Pharma, said in a press release. “This approval aligns with our core strategy of providing our customers with innovative and differentiated nuclear medicine products used for the diagnosis and treatment of diseases.” Drax Exametazime is a five, single-dose vial kit for preparing technetium (Tc)-99m exametazime for leukocyte (white blood cell) labeling scintigraphy, a nuclear medicine imaging procedure that helps clinicians localize abdominal infection and IBD. Scintigraphy is a diagnostic test in which radiopharmaceuticals are injected into specific tissues or organs, where emit gamma radiation. Using a gamma camera, physicians can obtain pelvic and abdominal images to assess gut health. Specifically, a buildup of radioactivity in the bowel with increasing intensity and/or no evidence of gastrointestinal (GI) motility — the natural movement of the digestive system — indicates IBD or infection. Conversely, radioactivity from hepatic excretion detected in the bowel four hours after an Drax Exametazime injection, and showing change in GI location in subsequent images, indicates normal motility. “The Health Canada approval further demonstrat
Subscribe or to access all post and page content.